SEARCH

SEARCH BY CITATION

References

  • 1
    Lienhardt C., Vernon A., Raviglione M.C. (2010) New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Curr Opin Pulm Med;16:186193.
  • 2
    Ma Z., Lienhardt C., Mcilleron H., Nunn A.J., Wang X. (2010) Global tuberculosis drug development pipeline: the need and the reality. Lancet;357:21002109.
  • 3
    Gillespie S.H., Billington O. (1999) Activity of moxifloxacin against Mycobacteria. J Antimicrob Chemother;4:393395.
  • 4
    Fung-Tome J., Minassian B., Kolck B., Washo T., Huczko E., Bonner D. (2000) In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. J Antimicrob Chemother;45:437446.
  • 5
    Moadebi S., Harder C. (2007) Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs;67:20772099.
  • 6
    Blumberg H.M., Burman W.J., Chaisson R.E., Daley C.L., Etkind S.C., Friedman L.N., Fujiwara P. et al. (2003) American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med;167:603662.
  • 7
    Koul A., Arnoult E., Lounis N., Guillemont J., Andries K. (2011) The challenge of new drug discovery for tuberculosis. Nature;469:483490.
  • 8
    Rodriguez J.C., Ruiz M., Climent A., Lopez M., Royo G. (2001) In vitro activity of four quinolones against Mycobacterium tuberculosis. Int J Antimicrob Agents;17:229231.
  • 9
    Rodriguez J.C., Ruiz M., Lopez M., Royo G. (2002) In vitro activity of moxifloxacin, levofloxacin, gatifloxacin, and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents;20:464467.
  • 10
    Shandil R.K., Jayaram R., Kaur P., Gaonkar S., Suresh B.L., Mahesh B.N., Jayashree R., Nandi V., Bharath S., Balasubramanian V. (2007) Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother;51:576582.
  • 11
    Bernardo J., Yew W.W. (2009) How are we creating fluoroquinolone-resistant tuberculosis? Am J Respir Crit Care Med;180:288289.
  • 12
    Devasia R.A., Blackman A., Gebretsadik T., Griffin M., Shintani A., May C., Smith T., Hooper N., Maruri F., Warkentin J., Mitchel E., Sterling T.R. (2009) Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med;180:365370.
  • 13
    Ginsburg A.S., Grosset J.H., Bishai W.R. (2003) Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis;3:432442.
  • 14
    Webster D., Long R., Shandro C., Petipas J., Leblanc J., Davidson R., Fanning A. (2010) Fluoroquinolone resistance in renale isolates of Mycobacterium tuberculosis. Int J Tuberc Lung Dis;14:217222.
  • 15
    Kam K.M., Yip C.W., Cheung T.L., Tang H.S., Leung O.C., Chan M.Y. (2006) Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility. Microb Drug Res;12:711.
  • 16
    Cheng A.F.B., Yew W.W., Chan E.W.C., Chin M.L., Hu M.M.M., Chan R.C.Y. (2004) Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother;48:596601.
  • 17
    Cecchetti V., Clementi S., Cruciani G., Fravolini A., Pagella P.G., Savino A., Tabarrini O. (1995) 6-Aminoquinolones: a new class of quinolone antibacterials? J Med Chem;39:973982.
  • 18
    Wise R., Pagella P.G., Cecchetti V., Fravolini A., Tabarrini O. (1995) In vitro activity of MF 5137, a new potent 6-aminoquinolone. Drugs;49:272273.
  • 19
    Cecchetti V., Fravolini A., Lorenzini M.C., Tabarrini O., Terni P., Xin T. (1996) Studies on 6-aminoquinolones: synthesis and antibacterial evaluation of 6-amino-8-methylquinolones. J Med Chem;39:436445.
  • 20
    Cecchetti V., Fravolini A., Palumbo M., Sissi C., Tabarrini O., Terni P., Xin T. (1996) Potent 6-desfluoro-8-methylquinolones as new lead compounds in antibacterial chemotherapy. J Med Chem;39:49524957.
  • 21
    Cecchetti V., Tabarrini O., Sabatini S., Miao H., Filipponi E., Fravolini A. (1999) Studies on 6-aminoquinolones: synthesis and antibacterial evaluation of 6-amino-8-ethyl- and 6-amino-8-methoxyquinolones. Bioorg Med Chem;7:24652471.
  • 22
    Tabarrini O., Sissi C., Fravolini A., Palumbo M. (2000) 6-Hydroxy derivative as new desfluoroquinolone (DFQ): synthesis and DNA-binding study. Nucleos Nucleot Nucl;19:13271336.
  • 23
    Jun N., Hideto F., Hisamitsu H., Hisato S., Wakao I., Tadashi A. (1993) Antibacterial 6-fluoro-quinolones having an oxime group on the substituent in position 7. EP 541085 A1.
  • 24
    Collins L., Franzblau S.G. (1997) Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother;41:10041009.
  • 25
    Cho S.H., Warit S., Wan B., Hwang C.H., Pauli G.F., Franzblau S.G. (2007) Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother;51:13801385.
  • 26
    Falzari K., Zhu Z., Pan D., Liu H., Hongmanee P., Franzblau S.G. (1997) In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. Antimicrob Agents Chemother;41:10041009.
  • 27
    Cecchetti V., Parolin C., Moro S., Pecere T., Filipponi E., Callistri A., Tabarrini O., Gatto B., Palumbo M., Fravolini A., Palù G. (2000) 6-Aminoquinolones as new potential anti-HIV agents. J Med Chem;43:37993802.
  • 28
    Tabarrini O., Stevens M., Cecchetti V., Sabatini S., Dell’uomo M., Manfroni G., Palumbo M., Pannecouque C., De Clercq E., Fravolini A. (2004) Structure modifications of 6-aminoquinolones with potent anti-HIV activity. J Med Chem;47:55675578.
  • 29
    Tabarrini O., Massari S., Cecchetti V. (2010) 6-Desfluoroquinolones as HIV-1 Tat-mediated transcription inhibitors. Future Med Chem;2:11611180.
  • 30
    Pucci M.J., Ackerman M., Thanassi J.A., Shoen C.M., Cynamon M.H. (2010) In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates. Antimicrob Agents Chemother;54:34783480.
  • 31
    Alangaden G.J., Lerner S.A. (1997) The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin Infect Dis;25:12131221.
  • 32
    Wiles J.A., Bradbury B.J., Pucci M.J. (2010) New quinolone antibiotics: a survey of the literature from 2005 to 2010. Expert Opin Ther Patents;20:12951319.
  • 33
    Feng L.S., Liu M.L., Zhang S., Chai Y., Wang B., Zhang Y.B., Lv K., Guan Y., Guo H.Y., Xiao C.L. (2011) Synthesis and in vitro antimycobacterial activity of 8-OCH(3) ciprofloxacin methylene and ethylene isatin derivatives. Eur J Med Chem;46:341348.
  • 34
    Tan C.K., Lai C.C., Liao C.H., Chou C.H., Hsu H.L., Huang Y., Hsueh P.R. (2009) Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother;64:428429.